TrialBritish journal of cancer2018

Trastuzumab and paclitaxel in patients with EGFR mutated NSCLC that express HER2 after progression on EGFR TKI treatment.

Adrianus J de Langen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.